A Utah overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Just over three in ten Utah adults have obesity: 31.0%, per the CDC's 2024 Behavioral Risk Factor Surveillance System survey 4 — up from 25.3% in 2017, a 5.7-point increase in seven years 4.
That trend is unfolding inside one of the country's fastest-growing states: Utah's population rose from 3,271,608 in April 2020 to 3,503,613 by July 2024, a 7.1% increase in four years, per the Census Bureau's Vintage 2024 estimates 5.
Utah Medicaid does pay for GLP-1 medications for weight loss — but only through a narrow, comorbidity-gated door, not as a general benefit. Under the fee-for-service Pharmacy Prior Authorization form "GLP-1 Medications for Weight-related Comorbidities (Saxenda, Wegovy, Zepbound)," last updated 6/1/2026 2, the state's Preferred Drug List keeps Ozempic, Mounjaro, Trulicity, and Rybelsus restricted to type 2 diabetes only 1.
Weight-loss coverage runs through three ongoing pathways: Wegovy for adults with a BMI of 27+ and a history of heart attack, stroke, or peripheral artery disease; Zepbound for moderate-to-severe obstructive sleep apnea (BMI 30+, sleep-study-confirmed AHI of 15+, documented PAP adherence); and Wegovy for biopsy- or imaging-confirmed liver fibrosis (MASH, stage F2-F3) under specialist management 2. None of those three carries a stated expiration date.
A fourth option on the same form, for obesity with none of those qualifying conditions, is explicitly labeled a "legislative pilot program" 2. Its authorization window runs only through 6/30/2026, and the form's reauthorization question requires proof of an existing approval dated between 7/1/2025 and 6/30/2026 — meaning the paperwork, as currently posted, offers a renewal path for patients already in the pilot but no visible route to a brand-new plain-obesity approval 2. Neither the Medicaid pharmacy program page 3 nor the PDL refreshed 8/1/2026 1 states whether the pilot was extended. Treat the plain-obesity pathway as unconfirmed past 6/30/2026 until Utah Medicaid Pharmacy Prior Authorization (855-828-4992) confirms current status — the three comorbidity pathways above remain the reliable route today.
Whatever the Medicaid pathway, most Utah adults seeking GLP-1 treatment for weight loss alone are paying cash, and pricing is where the picture becomes simple: Astra charges $68/month for semaglutide and $118/month for tirzepatide, billed annually at $816 and $1,416, in every state — Utah included. There's no city or state markup and no local discount; a patient in Provo pays the identical rate as a patient anywhere else.
That flat structure matters here specifically because Utah's median household income of $96,658 (ACS 2024) sits well above the national figure 6, yet 8.3% of Utahns — roughly 289,000 people — had no health insurance at all in 2024, per the same ACS release 67. For that uninsured share, and for anyone whose Medicaid plan doesn't fit one of the three comorbidity pathways above, a fixed, published cash price removes the biggest source of uncertainty in obesity treatment: not knowing what you'll be billed.
Beyond cost, Utah's obesity-care gap is largely about who's available to prescribe and manage treatment, not just who can pay. Obesity has climbed from 25.3% to 31.0% of adults in seven years 4 while Utah has simultaneously been one of the fastest-growing states in the country, adding roughly 232,000 residents between April 2020 and July 2024 5. Growth on both fronts strains the same small pool of endocrinologists and obesity-medicine specialists, concentrated mainly along the Wasatch Front, leaving much of the rest of the state with longer waits for an in-person specialist visit. Telehealth removes that bottleneck by putting a licensed clinician, prescription, and follow-up care on a phone or laptop instead of a waitlist.
Utah's specific telehealth prescribing rules sit with the Utah Division of Professional Licensing (DOPL). TODO: verify Utah's current telehealth-prescribing requirements directly with DOPL before this page goes live — informed consent, initial-visit modality, and any additional documentation for weight-loss prescriptions are not yet independently confirmed for this build.
Astra is licensed to treat patients in all 50 states, and that includes every part of Utah — Salt Lake City, Provo, St. George, Logan, and everywhere in between. There's no separate Utah-specific enrollment process: intake, prescribing, and pharmacy fulfillment work the same way here as they do nationally.
Astra treats patients in Utah through state-licensed physicians.
See our Provo page for city-specific data on obesity rates, local care options, and access in Utah County.
In narrow cases, yes. Utah Medicaid's fee-for-service pharmacy program covers Wegovy, Zepbound, or Saxenda through three specific comorbidity pathways: cardiovascular-risk reduction, moderate-to-severe obstructive sleep apnea, and MASH liver fibrosis — each requiring documented criteria and specialist involvement. A separate 'obesity alone' pathway exists but was authorized only as a legislative pilot through 6/30/2026, and the current paperwork appears limited to renewing existing approvals rather than starting new ones. If you're relying on Medicaid, confirm your specific eligibility with Utah Medicaid Pharmacy Prior Authorization (855-828-4992) — coverage rules here are unusually narrow and have an unresolved sunset date.
No. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide (billed as $816 or $1,416 annually) in every state, including Utah. There's no state or city markup and no local discount — the price a patient pays in Provo is identical to the price anywhere else Astra operates.
No. Most Utah patients pursuing weight-loss treatment don't have a qualifying comorbidity for the Medicaid pathways above, and specialist availability outside the Wasatch Front can mean long waits for an in-person visit. Telehealth lets a licensed clinician handle intake, prescribing, and follow-up remotely, which is the option most cash-pay patients in the state use today.
Yes. Astra is licensed in all 50 states, and that includes every part of Utah — Salt Lake City, Provo, St. George, Logan, and everywhere in between. See the Provo page for city-specific data on obesity rates and local care options.
Utah's Medicaid Preferred Drug List restricts Ozempic, Mounjaro, Trulicity, and Rybelsus to type 2 diabetes only — they aren't covered for weight loss at all. The drugs Medicaid will pay for on a weight-loss basis are specifically Wegovy, Zepbound, and Saxenda, and only through the comorbidity pathways described above.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.